Morgan Stanley Maintains 'Overweight' Rating on Hansoh Pharmaceutical with Target Price Lowered to HK$15

Morgan Stanley released a research report stating that it willHansoh Pharma(03692) cut its EPS forecast for 2023-25 by 5% to 12%, reflecting a conservative outlook on the company’s sales forecast, intensified anti-corruption efforts in China's pharmaceuticals industry, increased R&D expenses, and reduced sales expenses across each segment. Additionally, the target price for Hansoh Pharma was lowered from HK$17 to HK$15, while maintaining a "Buy" rating.

Editor: Shi Lijun